Form 4: ATAI Life Sciences Director Sabrina Martucci Johnson Granted 103,000 Stock Options

ATAI Life Sciences N.V. Director Sabrina Martucci Johnson was granted 103,000 stock options with an exercise price of $2.25, vesting by June 26, 2026, or earlier.

Summary

• Sabrina Martucci Johnson, a Director of ATAI Life Sciences N.V. (ATAI), was granted 103,000 stock options.
• The options have an exercise price of $2.25 per share.
• The grant date for these options was June 26, 2025.
• The options are set to expire on June 26, 2035.
• Vesting will occur on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns the director's interests with shareholders and incentivizes long-term performance. It is a standard compensation practice and does not indicate any negative operational or financial issues.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value creation.
• The exercise price of $2.25 provides an incentive for the director to contribute to the company's stock price appreciation.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The stock options are set to vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026, indicating a future milestone for the director's compensation. The options have a long-term expiration date of June 26, 2035, providing a long window for potential exercise.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize key personnel. This aligns the director's financial interests with the company's long-term performance and shareholder value creation, which is particularly relevant in industries requiring significant long-term R&D investment like life sciences.

Comparison to Industry Standards

• The grant of stock options as a form of director compensation is a standard practice across publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
• The specific number of options (103,000) and the exercise price ($2.25) would typically be evaluated against peer companies of similar market capitalization, stage of development, and industry within the life sciences sector to determine if it aligns with typical compensation packages for non-executive directors. Without specific peer data, a direct comparison is not possible from this document alone.
• The vesting schedule (earlier of next annual meeting or June 26, 2026) and the 10-year expiration period (until June 26, 2035) are also common structures for long-term incentive plans in the industry, designed to encourage sustained commitment and performance.

Related Party Transactions

• The stock option grant to a director could be considered a related party transaction, as it involves compensation from the company to a member of its board. However, it is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance. Dilution from future exercise is a minor consideration.

Next Steps

• The stock options will vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026.
• The director may exercise the options at any time after vesting and before the expiration date of June 26, 2035.

Key Dates

Recommendation

Keywords

ATAI Life Sciences, ATAI, Stock Option Grant, Sabrina Martucci Johnson, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Compensation, Biotechnology, Pharmaceuticals